UPS said it had reached an agreement in principle with its top customer to lower volume by more than 50% by the second half of 2026. "UPS Sees 2025 Revenue Slipping, Plans to Cut Volumes with Top ...

Wafaa Mamilli will join Roche as the company's new Chief Digital Technology Officer in February. This follows expansive roles she has held at Zoetis and at Eli Lilly.

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.

Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Global commercial executive with expertise across product lifecycle and therapeutic areas leading transformative brands, ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...